Early Stage Biomedical Articles & Analysis

1 news found

Shifa Biomedical Corporation Presents Preclinical Data on P-21, a Novel Orally Active PSCK9 Antagonist, at the American Heart Association (AHA) Meeting, Scientific Sessions 2018

P-21 is safe, as no liability issues were observed in vitro, in multiple cell based assays or in the vivo animal model. About Shifa Biomedical Corp. Shifa Biomedical Corporation (Shifa) is a drug discovery company in Malvern Pennsylvania. ...

Nov. 12, 2018

ByShifa Biomedical Corporation

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you